Gyre Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Aug '25 Aug 14, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	735	1,038	1,967	-
Market Cap Growth	-34.68%	-47.22%	-	-
Enterprise Value	684	1,050	1,946	-
Last Close Price	8.21	12.10	25.69	-
PE Ratio	176.85	85.93	-	-
PS Ratio	6.95	9.82	17.34	-
PB Ratio	8.10	10.55	25.07	-
P/TBV Ratio	8.46	16.85	-	-
P/FCF Ratio	-	-	113.23	-
P/OCF Ratio	-	-	75.99	-
EV/Sales Ratio	6.69	9.93	17.15	-
EV/EBITDA Ratio	60.25	58.96	95.72	-
EV/EBIT Ratio	73.18	64.73	101.27	-
EV/FCF Ratio	-	-	111.99	-
Debt / Equity Ratio	0.01	0.02	0.01	0.01
Debt / EBITDA Ratio	0.11	0.09	0.02	0.06
Debt / FCF Ratio	-	-	0.02	0.11
Asset Turnover	0.75	0.87	1.13	-
Inventory Turnover	0.58	0.73	0.89	-
Quick Ratio	4.68	2.64	2.49	3.33
Current Ratio	5.40	3.32	2.85	4.06
Return on Equity (ROE)	7.84%	20.24%	-113.45%	-
Return on Assets (ROA)	4.27%	8.38%	11.93%	-
Return on Capital (ROIC)	5.16%	11.34%	15.83%	-
Return on Capital Employed (ROCE)	6.90%	15.30%	19.90%	12.70%
Earnings Yield	0.57%	1.16%	-4.72%	-
FCF Yield	-	-0.57%	0.88%	-
Buyback Yield / Dilution	-33.83%	-55.39%	13.02%	-

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q